Compare DexCom, Inc. (DXCM) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Morgan Stanley — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while Morgan Stanley trades at $220.23 (market cap $359.28B). The key difference: Morgan Stanley is far larger — about 12.8× DexCom, Inc.'s market cap, and Morgan Stanley pays a 1.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MS | |
|---|---|---|
Market Cap | $28.06B | $359.28B |
Sector | Health | Financials |
52-Week High | $89.53 | $228.42 |
52-Week Low | $54.84 | $139.09 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Morgan Stanley (MS) trades at $228.17, up 3.2% with strong technical and fundamental momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth from $57.6B in 2024 to $66.0B in 2025. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus at Buy (53.85%) and $229 price target. Key opportunities include sustained earnings growth and strategic initiatives, while risks involve volatile cash flows and high debt levels. The stock presents a balanced risk-reward profile for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
